Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Anemia 38Neoplasms 26Breast Neoplasms 4Multiple Myeloma 2Leukemia 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Red-Cell Aplasia, Pure 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma 1

Interventions

sagopilone 1pembrolizumab 1nabilone 1eribulin 1enfortumab vedotin 1allantoicase 1Prednisolone 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Lenalidomide 1Exercise 1Epoetin Alfa 1BID protein, human 1Acetylcarnitine 14-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peripheral Nervous System Diseases × Epoetin Alfa × Clear all
NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡